ABSTRACT Though efficacy of Allergen Specific Immunotherapy (ASIT) has been proved in many studies, reports about success in clinical practice and under field conditions in alleviating the suffering or decreasing the morbidity in patients of Allergic Rhinitis are few. 260 patients of Allergic Rhinitis without coexisting diseases were included. Skin prick test was done on all patients. ASIT was initiated with common inhalant indoor allergens as per standard protocol and patients were assessed at the start and at 2 m, 6 m and 18 months of ASIT. ASIT was able to significantly reduce the symptom score in all the three groups namely sneezing, rhinorrhoea and nasal itching (p < 0.001). Concurrently it was also able to produce a significant reduction in the usage of concomitant drug intake (p < 0.001) thereby implying a decrease in morbidity. When assessed regarding clinical efficacy, ASIT was found to be satisfactory or highly effective in more than 75% patients. ASIT has got a role in clinical practice in polysensitized patients in field conditions. This is based on the evidence that besides decrease in hypersensitivity/symptoms, it also has an effect on minimizing the necessity of taking drugs to relieve the symptoms, which has strong implications of economics and toxicity, while treating patients.
Cite this paper
nullR. Sukhesh, "Clinical Efficacy of Allergen Specific Immunotherapy (ASIT) in Allergic Rhinitis," International Journal of Clinical Medicine, Vol. 2 No. 4, 2011, pp. 394-398. doi: 10.4236/ijcm.2011.24066.
 J. Freeman and I. Noon, “Further Observation on the Treatment of Hay Fever by Hypodermic Inoculation of Pollen Vaccine,” Lancet, Vol. 2, 1911, pp. 814-816.
 L. Jacobson and E. Valovivta, “How Strong Is the Evidence That Immunotherapy in Children Prevents the Progression of Allergy and Asthma,” Current Opinion in Allergy and Clinical Immunology, Vol. 7, No. 6, 2007, pp. 556-561. doi:10.1097/ACI.0b013e3282f1d67e
 I. Finegold, “Is Immunotherapy Effective in Allergic Diseases?” Current Opinion in Allergy and Clinical Immunology, Vol. 2, No. 6, 2002, pp. 537-540.
 M. Calderon, B. Alves, M. Jacobson, et al., “Allergen Injection Immunotherapy for Seasonal Allergic Rhinitis,” Cochrane Database of Systematic Reviews, Vol. 1, 2007, p. CD001936.
 H.S. Nelson, J. Lahr, R. Rule, A. Bock and D. Leung, “Treatment of Anaphylactic Sensitivity to Peanuts by Immunotherapy with Injections of Aqueous Peanut Extract,” The Journal of Allergy and Clinical Immunology, Vol. 99, No. 6, 1997, pp. 744-751.
 A. Didier, M. Melac, A. Mantagut, M. Lheretier-Barrand, A. Tabor and M. Worn, “Agreement of Efficacy Assessment for Five Grass—Pollen Sublingual Tablet in Immunotherapy,” Allergy, Vol. 64, No. 1, 2008, pp. 166- 171.
 J. M. Portnoy, “Immunotherapy for Inhalant Allergies: Guidelines for Why, When & How to Use This Treatment,” Postgraduate Medical Journal, Vol. 100, 2001, pp. 89-106.
 J. Susmitha, V. Vijayalaxmi, G. Sumanlatha and K. J. R. Murthy, “Combination of Allergens in Specific Immunotherapy for IgE Mediated Allergies,” Lung India, Vol. 24, No. 1, 2007, pp. 3-5.
 G. W. Canonica, C. E Baena-Cagnani., J. Bousquet, P. J. Bousquet, R. F. Lockey, H. T. Mailing, et al., “Recommendations for Standardizations for Clinical Trials with Allergen Specific Immunotherapy for Respiratory Allergy. A Statement of WHO Task Force,” Allergy, Vol. 62, No. 3, 2007, pp. 317-324.
 J. Clark and R. Schall, “Assessment of Combined Symptom & Medication Scores for Rhino Conjunctivitis Immunotherapy Clinical Trials,” Allergy, Vol. 62, No. 9, 2007, pp. 1023-1028.
 G. Passalacqua and S. R. Durham, “Allergic Rhinitis and Its Impact on Asthma Update & Allergen Immunotherapy,” The Journal of Allergy and Clinical Immunology, Vol. 119, No. 4, 2007, pp. 881-891.
 H. J. Malling, “Immunotherapy as An Effective Tool in Allergy Treatment,” Allergy, Vol. 53, No. 5, 1998, pp. 461-472.
 H. J. Malling, “New ideas in Allergen Specific Immunotherapy,” American Journal of Rhinology, Vol. 4, No. 4, 1990, pp. 155-158. doi:10.2500/105065890782018136